Skip to main content

Pharvaris To Present at the 18th German Allergy Congress

Written by Customer Service on . Posted in Public Companies.

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023.

Presentation details:

  • Title: Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
    Presenter: Emel Aygören-Pürsün, M.D.
    Date, Time: Friday, September 15, 5:15-6:30 p.m. CEST
    Poster ID: A-194
  • Title: Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
    Presenter: Markus Magerl, M.D.
    Date, Time: Friday, September 15, 5:15-6:30 p.m. CEST
    Poster ID: A-264

The abstracts will be published in the congress issue of the Allergo Journal International and Allergologie. After the close of the ePoster session “Angioedema,” the posters will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

CONTACT: Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
Maggie.beller@pharvaris.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.